May 10, 2024 03:55 PM EDTUpdated May 12, 07:49 AM

New Biosecure draft features 2032 grandfather clause, five-year grace period for added companies

Lia DeGroot

Drugmakers would have until 2032 to cut ties with WuXi AppTec and other Chinese life sciences companies, according to an updated draft of the closely …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

New Biosecure draft features 2032 grandfather clause, five-year grace period for added companies

Lia DeGroot

Sign up to read this article for free.

Vertex’s non-opioid pill disappoints in mid-stage chronic pain study

David Epstein gets $140M for Ottimo's bifunctional take on hot PD-1xVEGF field

Roche’s Parkinson’s drug flunks second mid-stage trial

Sangamo strikes another brain-targeting AAV partnership, this time with Astellas

Novartis turns to BioAge for new targets based on longevity and exercise

Exclusive: Color Health alums raise $10M for new startup, using AI for regulatory work

New Biose­cure draft fea­tures 2032 grand­fa­ther clause, five-year grace pe­ri­od for added com­pa­nies

Lia DeGroot

Sign up to read this article for free.

more like this

Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

David Ep­stein gets $140M for Ot­ti­mo's bi­func­tion­al take on hot PD-1xVEGF field

Roche’s Parkin­son’s drug flunks sec­ond mid-stage tri­al

Sang­amo strikes an­oth­er brain-tar­get­ing AAV part­ner­ship, this time with Astel­las

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Ex­clu­sive: Col­or Health alums raise $10M for new start­up, us­ing AI for reg­u­la­to­ry work

New Biosecure draft features 2032 grandfather clause, five-year grace period for added companies

Vertex’s non-opioid pill disappoints in mid-stage chronic pain study

David Epstein gets $140M for Ottimo's bifunctional take on hot PD-1xVEGF field

Roche’s Parkinson’s drug flunks second mid-stage trial

Sangamo strikes another brain-targeting AAV partnership, this time with Astellas

Novartis turns to BioAge for new targets based on longevity and exercise

Exclusive: Color Health alums raise $10M for new startup, using AI for regulatory work